PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
Jotup,
“We believe this important therapy will have a significant impact on patients with schizophrenia if approved by the FDA.
“We believe this important therapy will have a significant impact on patients with schizophrenia if approved by the FDA.
BOSTON
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated…
Royalty Pharma has acquiredan interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will…